
Opinion|Videos|May 10, 2024
Neoadjuvant Approach in RAI-R-DTC
Medical experts discuss the role of neoadjuvant therapy in the setting of differentiated thyroid cancer (DTC) and examine current trials exploring its potential.
Advertisement
Episodes in this series

Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC
3
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
4
DeLLphi-305 Moves Tarlatamab Into First-Line Maintenance for ES-SCLC
5


